![]() |
市場調查報告書
商品編碼
1832018
2025 年至 2033 年醫藥過濾市場規模、佔有率、趨勢及預測(依產品、技術、應用、營運規模及地區分類)Pharmaceutical Filtration Market Size, Share, Trends and Forecast by Product, Technique, Application, Scale of Operation, and Region, 2025-2033 |
2024年,全球醫藥過濾市場規模達160.5億美元。展望未來, IMARC Group預測,到2033年,該市場規模將達到723.6億美元,2025年至2033年的複合年成長率為17.30%。由於生物製藥需求不斷成長、監管標準日益嚴格、技術持續進步以及對藥品安全的日益關注,北美目前佔據市場主導地位,2024年的市場佔有率將超過45.6%。
隨著藥品、生物製劑和疫苗品質要求的不斷提高,製藥過濾市場呈現擴張態勢。製藥製造商力求達到嚴格的品質和安全標準,先進過濾系統的需求也隨之成長,以確保產品純度。藥物製劑透過高效過濾,去除污染物、微生物和顆粒物,達到安全標準並保持高效性能。為此,薄膜過濾、深層過濾和無菌過濾等現代過濾技術擁有先進的過濾性能,能夠滿足不斷變化的產業需求。此外,對能夠執行個人化醫療和生物製劑複雜生產流程的專用過濾系統的需求也在持續成長。
在美國,受政府加大對醫療基礎設施投資以及製藥和生物技術行業蓬勃發展的推動,製藥過濾市場正在經歷顯著成長。例如,2024年9月,美國政府宣佈向北卡羅來納州投資390萬美元的EDA(電子設計自動化),用於改善支援生物技術和醫療保健產業的基礎設施。美國政府擁有嚴格的監管體系,尤其是透過FDA標準,促使製藥公司採用高品質的過濾系統。此外,將製藥生產外包給合約生產組織(CMO)的趨勢日益成長,也增加了對符合全球藥品安全和合規標準的過濾技術的需求。
製藥和生物技術行業支出不斷增加
製藥公司正在大力投資研發,尤其是在生物技術領域,這需要先進的過濾技術用於蛋白質純化和細胞培養等製程。例如,據報道,大型製藥企業通常將其20%的收益用於研發。此外,製藥公司阿斯特捷利康在2023年將其處方藥收益的23%以上用於研發。此外,包括單株抗體和重組蛋白在內的生物製藥的興起需要專門的過濾方法來確保產品品質和產量。這些因素進一步推動了製藥過濾市場的成長。
學名藥需求不斷成長
學名藥需求的不斷成長是推動醫藥過濾市場成長的重要因素之一。例如,根據IMARC的數據,全球學名藥市場規模在2023年達到3,671億美元。展望未來, IMARC Group預計到2032年,該市場規模將達到6,280億美元,2024-2032年期間的複合年成長率(CAGR)為5.96%。學名藥需要大量生產以滿足全球需求,因此需要高效且可擴展的過濾製程來確保品質和合規性。這些因素進一步對醫藥過濾產業的預測產生了正面的影響。
慢性病盛行率不斷上升
慢性病盛行率的上升帶來了對各種藥物的需求。據估計,到2030年,四大非傳染性疾病將導致全球75%的死亡。新藥不斷湧現,旨在治療癌症、糖尿病、氣喘、慢性阻塞性肺病和關節炎等慢性疾病。例如,2023年12月,阿斯特捷利康製藥印度公司推出了曲妥珠單抗Deruxtecan(又稱Enhertu),用於治療HER2陽性乳癌。每一款新藥的上市通常都需要擴大產量以滿足市場需求。產量的增加與對過濾技術更高需求的直接相關,以確保產品品質和法規合規性。這些因素進一步提升了製藥過濾市場佔有率。
The global pharmaceutical filtration market size was valued at USD 16.05 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 72.36 Billion by 2033, exhibiting a CAGR of 17.30% from 2025-2033. North America currently dominates the market, holding a market share of over 45.6% in 2024, due to the escalating demand for biopharmaceuticals, stringent regulatory standards, ongoing technological advancements, and growing focus on drug safety.
The pharmaceutical filtration market shows expansion because of escalating requirements for medicines, biologics, and vaccine quality. As pharmaceutical manufacturers aim to achieve strict quality and safety standards, the requirement for advanced filtration systems for product purity has grown. Drug formulations achieve their safety standards along with effective performance through filtration which efficiently eliminates contaminants, microorganisms, and particulates. In line with this, modern filtration technologies such as membrane filtration, depth filtration, and sterile filtration have advanced filtration performance to match the changing industry requirements. Furthermore, the growing demand for specialized filtration systems that can execute complex production processes of personalized medicine and biologics continues to rise.
In the United States, the pharmaceutical filtration market is experiencing significant growth driven by increasing government investments in healthcare infrastructure and the expanding pharmaceutical and biotech sectors. For instance, in September 2024, U.S. government announced a USD 3.9 million EDA investment in North Carolina for infrastructure improvements supporting biotechnology and healthcare sectors. The country maintains strong regulatory oversight especially through FDA standards which drives drug manufacturers to embrace high-quality filtration systems. Furthermore, the growing trend of outsourcing pharmaceutical manufacturing to contract manufacturing organizations (CMOs) enhances demand for filtration technologies that meet global standards for drug safety and compliance.
Rising Spending in Pharmaceutical and Biotechnological Industries
Pharmaceutical companies are investing heavily in research and development, particularly in biotechnology, which requires advanced filtration technologies for processes such as protein purification and cell culture. For instance, according to reports, large pharmaceutical businesses typically dedicate 20% of their earnings to research and development. Also, AstraZeneca, a pharmaceutical company, spent more than 23% of its prescription drug earnings in 2023 on research and development. Moreover, the rise in biopharmaceuticals, including monoclonal antibodies and recombinant proteins, requires specialized filtration methods to ensure product quality and yield. These factors are further driving the pharmaceutical filtration market growth.
Increasing Demand for Generic Drugs
The increasing demand for generic drugs is one of the prominent factors driving the growth in the pharmaceutical filtration market. For instance, according to IMARC, the global generic drugs market size reached USD 367.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 628.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.96% during 2024-2032. Generic drugs are manufactured in large volumes to meet global demand, necessitating efficient and scalable filtration processes to ensure quality and regulatory compliance. These factors are further positively influencing the pharmaceutical filtration industry forecast.
Growing Prevalence of Chronic Diseases
The increased prevalence of chronic diseases increases the demand for a variety of medications. It is estimated that the four major noncommunicable diseases will be responsible for 75% of worldwide deaths by 2030. New medications are introduced to address chronic conditions, such as cancer, diabetes, asthma, COPD, and arthritis. For instance, in December 2023, AstraZeneca Pharma India launched Trastuzumab Deruxtecan, also known as Enhertu, which is used to treat HER2-positive breast cancer. Each new drug launch typically requires scaled-up production to meet the market demand. This increased manufacturing volume directly correlates with higher demand for filtration technologies to ensure product quality and regulatory compliance. These factors are further contributing to the pharmaceutical filtration market share.
Membrane filters stand as the largest product in 2024, holding around 27.8% of the market. Membrane filters are essential in pharmaceutical manufacturing for processes, such as sterile filtration, virus filtration, and protein purification. They are used in bioprocessing applications for cell culture clarification, concentration, and separation of biomolecules. In research laboratories, they are applied for sample preparation, microbiological analysis, and removing particles among a variety of scientific experiments. For instance, in December 2023, TeraPore Technologies, a nanofiltration membranes company, launched IsoBlock VF product line and IsoBlock PF Syringe Prefilter Device for parvovirus elimination from biopharmaceuticals. The IsoBlock PF Syringe Prefilter Device is an adsorptive membrane-based prefilter that removes undesired high-molecular-weight species from the feed prior to size-based virus removal.
Microfiltration leads the market with around 37.6% of market share in 2024. As per the pharmaceutical filtration market outlook, microfiltration is commonly used for sterile filtration to remove microorganisms and particles from pharmaceutical solutions and suspensions. This process is critical in preparing sterile drug products, such as injectables, ophthalmic solutions, and parenteral nutrition solutions. Moreover, it is used for clarification and particle removal in pharmaceutical manufacturing processes. The increasing demand for biologics and biosimilars further drives its adoption, as these products require stringent contamination control. The rising need for biologics together with biosimilars promotes the growth of microfiltration due to their strict requirements for contamination control.
Final product processing leads the market with around 43.7% of market share in 2024. Pharmaceutical filtration during final product processing remains essential for product safety, efficacy, and quality outcomes in the market. Additionally, pharmaceutical solutions and suspensions require sterile filtration to take out microorganisms and particles for achieving stringent sterility requirements. The procedure of sterile filtration eliminates microbiological contaminants present in end-stage drug products, including vaccines and antibiotics along with ophthalmic solutions and other sterile formulations.
Manufacturing scale leads the market with around 67.8% of market share in 2024. The pharmaceutical industry produces medications at industrial levels to fulfill worldwide medicine needs. This high product volume demands powerful filtration methods that guarantee safe and dependable product quality. In addition, the implementation of safety standards and efficacy requirements by regulatory bodies remains enforced upon pharmaceutical manufacturers for ensuring product safety and purity. The manufacturing volumes of biologics, biosimilars, and complex drug formulations demand innovative filtration technologies as an essential necessity. Besides this, technological improvements in filtration systems boost operational productivity by minimizing contamination hazards and bettering output volumes as well as maintaining adherence to strict industry standards.
In 2024, North America accounted for the largest market share of over 45.6%. The region has a strong presence of biopharmaceutical companies engaged in the production of biologics, vaccines, and biosimilars. For instance, in April 2024, Bavarian Nordic A/S, a fully integrated vaccine company, launched Jynneos, the only FDA-approved mpox vaccine in the United States. This sector requires advanced filtration technologies for processes like sterile filtration, virus filtration, and ultrafiltration/diafiltration (UF/DF). Moreover, continued investments in research and development by pharmaceutical companies and academic institutions fuel innovation in filtration technologies, supporting the market growth.
United States Pharmaceutical Filtration Market Analysis
In 2024, United States accounted for 80.50% of the market share in North America. Pharmaceutical filtration is gaining widespread adoption due to increasing investments in healthcare. For instance, U.S. healthcare companies securing venture capital deals of USD 15 Million plus are driving robust investment growth, focusing on innovation in medical technology to meet rising market demands. As governments and private entities inject substantial funding into the healthcare sector, there is a notable shift towards modernizing medical infrastructure and improving treatment options. This surge in investment has led to an expansion of pharmaceutical production facilities, which in turn demands high-quality filtration solutions for drug production and purification processes. The need for sterile and safe drug formulations requires the use of advanced filtration technologies that can meet stringent quality standards. As healthcare systems grow and evolve, pharmaceutical filtration systems are increasingly seen as essential in maintaining the efficiency, safety, and effectiveness of the drug development process, contributing to the overall improvement of public health.
Europe Pharmaceutical Filtration Market Analysis
In Europe, the growing adoption of pharmaceutical filtration is driven by the rising incidence of chronic diseases and the aging population. For instance, Europe's ageing population is on the rise, with one in five Europeans now aged 65 or older, projected to approach 30% by 2050. As the elderly population continues to increase, so does the prevalence of chronic conditions such as diabetes, hypertension, and cardiovascular diseases. The need for continuous treatment and management of these conditions has boosted the demand for pharmaceutical products. This, in turn, has led pharmaceutical companies to invest in advanced filtration technologies to ensure the quality and safety of their products. The aging population requires long-term care, driving the need for innovative filtration solutions to support the production of high-quality medicines. With healthcare providers striving to meet the needs of an aging demographic, pharmaceutical filtration has become a critical element in ensuring the efficacy and safety of treatments, improving patient outcomes.
Asia Pacific Pharmaceutical Filtration Market Analysis
The adoption of pharmaceutical filtration has seen a significant rise in response to the growing demand for generic medicines. According to National Informatics Centre (NIC), India is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume. The industry manufactures about 60,000 different generic brands across 60 therapeutic categories. With a rapidly increasing population, more individuals are seeking access to medications, and generic drugs have become a popular alternative to branded drugs due to their affordability. The demand for these medicines has led to a rise in pharmaceutical production, which necessitates the implementation of filtration processes to ensure that the final products are free from contaminants. As the need for high-quality, affordable drugs grows, pharmaceutical companies are investing more in filtration technologies to maintain the safety, purity, and compliance of the medications they produce, meeting the growing healthcare needs of the population.
Latin America Pharmaceutical Filtration Market Analysis
The growing adoption of pharmaceutical filtration in Latin America is attributed to the expanding private healthcare sector. According to International Trade Administration, Brazil is the largest healthcare market in Latin America with 7,191 hospitals, 62% are private. With increasing investments in private healthcare infrastructure, more facilities are being established to cater to the growing demand for quality medical services. The shift towards privatization has led to improvements in healthcare services, with a focus on adopting advanced technologies such as filtration systems. These innovations play a crucial role in enhancing the quality of medicines and ensuring that pharmaceutical products meet international standards. As the private sector grows, pharmaceutical manufacturers are adopting filtration systems to meet stricter regulatory standards and improve product safety, driving the increased use of these technologies in the region.
Middle East and Africa Pharmaceutical Filtration Market Analysis
In the Middle East and Africa, the growing adoption of pharmaceutical filtration is driven by the expansion of healthcare facilities. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. With governments and private sector entities investing heavily in healthcare infrastructure, the need for advanced pharmaceutical filtration technologies has risen. These investments are aimed at improving the quality of healthcare services, which includes the production of medicines that adhere to international safety and quality standards. As healthcare facilities expand, pharmaceutical companies are incorporating filtration solutions to meet these standards and improve product safety. The development of healthcare infrastructure in the region is expected to continue driving the demand for pharmaceutical filtration systems, ensuring the availability of safe and effective treatments for the population.
The pharmaceutical filtration market remains competitive because companies focus on enhancing their technological capabilities while ensuring high product quality and following strict regulatory requirements. Moreover, businesses dedicate research investments for developing cutting-edge filtration systems that include membrane filters, sterile filtration, and depth filtration to serve the expanding requirements of drug producing companies alongside biologics producers and vaccine developers. For instance, in October 2024, Asahi Kasei Medical launched the Planova(TM) FG1, a high-flux virus removal filter. It enables time-saving filtration operations while achieving superior virus removal rates and harmonizing with common cleaning procedures which enhances the productivity of pharmaceutical manufacturing. The market demand for high-quality biologic and pharmaceutical products drives competitor focus on offering reliable filtration technologies at cost-effective prices and efficient solutions. In addition, the pharmaceutical sector shows market consolidation due to partnerships and acquisitions which help companies enhance their global pharmaceutical operations through expanded product offerings.